Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adsorbed Tetanus Vaccine in Adults
NCT07598890Phase 1Active, not recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tetanus vaccine in Tetanus (2 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoint: Incidence of adverse events (AEs) and adverse reactions (ARs) at 7 days. Started May 2026; status: active, not recruiting.
02
Drugs
tetanus vaccine
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT07598890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598890.